Silymarin, a milk thistle seed extract, supports the liver by easing oxidative damage, inflammation, and scarring. Its strongest use is shielding liver cells from toxins, including emergency treatment for death cap mushroom poisoning. Everyday effects on liver, blood sugar, and cholesterol are modest, clearest in people starting with abnormal values. Very well tolerated; product quality is the main concern. (Full Review)

Protocol

Dose

140 mg × 2–3 daily

≈420 mg/day standardized silymarin; up to 600–700 mg/day for fatty liver

Timing

Split with meals

2–3 doses/day tied to meals for absorption; no circadian preference

Form

Standardized extract

Legalon-type; silibinin-phosphatidylcholine complex to overcome poor absorption

Time to effect

Liver enzymes

8–12 weeks

Gradual decline in liver enzymes with consistent use

Metabolic markers

8–12 weeks

Blood sugar and cholesterol improvements

Reassess

~12 weeks

Recheck markers; continue only if benefit is evident

Benefits

High: Hepatoprotection against toxin- and drug-induced liver injury

Medium: Reduced liver fat and enzymes in metabolic fatty liver disease; improved glycemic control and insulin sensitivity; improved lipid profile

Low: Systemic anti-inflammatory and antioxidant effects; modest blood pressure reduction

Speculative: Cancer chemoprevention; neuroprotection and cognitive support; longevity and cellular-aging pathways

Contraindications

Asteraceae-family plant allergy (ragweed, daisies, marigolds, chrysanthemums)

Pregnancy and breastfeeding

Discontinue before major surgery

Key Interactions

Antidiabetic drugs (metformin, sulfonylureas, insulin)

CYP2C9 substrates (warfarin, losartan, phenytoin)

CYP3A4 substrates (sirolimus, certain statins, some chemotherapies)

Hormone-sensitive cancers

Glucose-lowering supplements (berberine, chromium, alpha-lipoic acid)

Risk & Side Effects

High: Gastrointestinal effects

Medium: Allergic and hypersensitivity reactions; additive blood-sugar lowering with antidiabetic therapy

Low: Herb–drug interactions via metabolic enzymes and transporters; estrogenic activity

Speculative: Rare anaphylaxis and severe reactions; blunting of exercise-induced adaptations

Monitoring

Marker	Target	Why
ALT	<25 U/L (women), <30 U/L (men)	Primary marker of liver-cell stress
AST	<25 U/L	Complements ALT for liver-cell injury
GGT	<25 U/L	Sensitive marker of liver/bile stress and oxidative burden
Fasting glucose	75–90 mg/dL	Tracks glycemic benefit and hypoglycemia risk
HbA1c	<5.4%	Average blood sugar over ~3 months
Fasting insulin	2–5 µIU/mL	Detects insulin resistance and response
Lipid panel (LDL, TG, HDL)	TG <80, HDL >50 mg/dL; LDL context-dependent	Tracks lipid response
hs-CRP	<1.0 mg/L	Systemic inflammation marker

Cadence: Baseline before starting, then ~12 weeks after starting, then every 6–12 months if continued; weekly glucose in the first month when combined with antidiabetic therapy

Qualitative Assessment

Energy levels and daytime alertness
Digestive comfort (absence of bloating or loose stools indicating good tolerance)
General sense of well-being
Absence of allergic symptoms such as rash or itching

Silymarin for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment